To What Extent Do the NRS and CRQ Capture Change in Patients' Experience of Breathlessness in Advanced Disease? Findings From a Mixed-Methods Double-Blind Randomized Feasibility Trial
- PMID: 31201877
- DOI: 10.1016/j.jpainsymman.2019.06.004
To What Extent Do the NRS and CRQ Capture Change in Patients' Experience of Breathlessness in Advanced Disease? Findings From a Mixed-Methods Double-Blind Randomized Feasibility Trial
Abstract
Context: Chronic or refractory breathlessness is common and distressing. To evaluate new treatments, outcome measures that capture change in patients' experience are needed.
Objectives: To explore the extent to which the numerical rating scale (NRS) worst and average, and the Chronic Respiratory Questionnaire capture change in patients' experience during a trial of mirtazapine for refractory breathlessness.
Methods: Convergent mixed-methods design embedded within a randomized trial comprising 1) semi-structured qualitative interviews (considered to be the gold standard) and 2) outcome measure data collected pre- and post-intervention. Data were integrated, exploring examples where findings agreed and disagreed. Adults with advanced cancer, chronic obstructive pulmonary disease, interstitial lung disease, or chronic heart failure, with a modified Medical Research Council dyspnea scale grade 3 or 4 were recruited from three U.K. sites.
Results: Data were collected for 22 participants. Eleven had a diagnosis of chronic obstructive pulmonary disease, eight interstitial lung disease, two chronic heart failure, and one cancer. Median age was 71 (56-84) years. Sixteen participants were men. Changes in the qualitative data were commonly captured in the NRS (worst and average) and the Chronic Respiratory Questionnaire. The NRS worst captured change most frequently. Improvement in the emotional domain was associated with physical changes, improved confidence, and control.
Conclusion: This study found that the NRS using the question "How bad has your breathlessness felt at its worst over the past 24 hours?" captured change across multiple domains, and therefore may be an appropriate primary outcome measure in trials in this population. Future work should confirm the construct validity of this question.
Keywords: Breathlessness; advanced disease; outcome measure; randomized controlled trial; shortness of breath.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
-
What influenced people with chronic or refractory breathlessness and advanced disease to take part and remain in a drug trial? A qualitative study.Trials. 2020 Feb 22;21(1):215. doi: 10.1186/s13063-020-4129-2. Trials. 2020. PMID: 32087745 Free PMC article. Clinical Trial.
-
Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial.Lancet Respir Med. 2024 Oct;12(10):763-774. doi: 10.1016/S2213-2600(24)00187-5. Epub 2024 Sep 9. Lancet Respir Med. 2024. PMID: 39265600 Clinical Trial.
-
Breathlessness during daily activity: The psychometric properties of the London Chest Activity of Daily Living Scale in patients with advanced disease and refractory breathlessness.Palliat Med. 2017 Oct;31(9):868-875. doi: 10.1177/0269216316680314. Epub 2016 Dec 15. Palliat Med. 2017. PMID: 27932629 Free PMC article.
-
Pathophysiological mechanisms of exertional breathlessness in chronic obstructive pulmonary disease and interstitial lung disease.Curr Opin Support Palliat Care. 2018 Sep;12(3):237-245. doi: 10.1097/SPC.0000000000000377. Curr Opin Support Palliat Care. 2018. PMID: 30074922 Review.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
Cited by
-
Association of patient-reported outcome measures with lung function and mortality in fibrotic interstitial lung disease: a prospective cohort study.ERJ Open Res. 2024 Mar 25;10(2):00591-2023. doi: 10.1183/23120541.00591-2023. eCollection 2024 Mar. ERJ Open Res. 2024. PMID: 38529347 Free PMC article.
-
Danish translation and linguistic validation of the multidimensional dyspnea profile.Eur Clin Respir J. 2021 Mar 30;8(1):1905498. doi: 10.1080/20018525.2021.1905498. Eur Clin Respir J. 2021. PMID: 33854743 Free PMC article. No abstract available.
-
Modified-release morphine or placebo for chronic breathlessness: the MABEL trial protocol.ERJ Open Res. 2023 Aug 14;9(4):00167-2023. doi: 10.1183/23120541.00167-2023. eCollection 2023 Jul. ERJ Open Res. 2023. PMID: 37583966 Free PMC article.
-
Differences in uni-dimensional breathlessness measures and thresholds for clinical response in a randomised controlled trial in people with chronic breathlessness: an exploratory study.BMJ Open Respir Res. 2024 Dec 4;11(1):e002370. doi: 10.1136/bmjresp-2024-002370. BMJ Open Respir Res. 2024. PMID: 39632100 Free PMC article. Clinical Trial.
-
Recent advances in understanding the role of antidepressants to manage breathlessness in supportive and palliative care.Curr Opin Support Palliat Care. 2025 Jun 1;19(2):83-94. doi: 10.1097/SPC.0000000000000761. Epub 2025 Apr 21. Curr Opin Support Palliat Care. 2025. PMID: 40265531 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous